Transactions
10
Insider / VERTEX PHARMACEUTICALS INC / MA
Bunnage Mark E.
EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA
- Ticker
- VRTX
- First filing on record
- February 12, 2026
- Latest trade on record
- May 15, 2026
- SEC filings
- EDGAR ↗
Bunnage Mark E., EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA, has disclosed 10 transactions in VRTX since February 12, 2026: 0 purchases (0 open-market buys) and 9 sales, worth about $5.5M at the reported prices. The latest was filed May 19, 2026, 4 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
9
Avg. disclosure lag
2.2d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Bunnage Mark E. made no purchases and 9 sales worth $5.5M, plus 1 other transaction. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Bunnage Mark E. has traded 1 stock on record; the largest by dollars is VRTX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 5 | 6,293 | $3.0M |
| F | Shares withheld for tax | 4 | 5,102 | $2.5M |
| A | Grant or award | 1 | 2,584 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 10 | 0 | 9 · $5.5M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| VRTX | Sell S | May 15, 2026 | May 19, 2026 | 4d | 33 | $453 | $15K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell S | February 25, 2026 | February 26, 2026 | 1d | 620 | $486 | $302K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell F | February 24, 2026 | February 26, 2026 | 2d | 582 | $485 | $282K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell S | February 18, 2026 | February 19, 2026 | 1d | 1,182 | $474 | $560K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell S | February 17, 2026 | February 19, 2026 | 2d | 2,437 | $489 | $1.2M | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell F | February 17, 2026 | February 19, 2026 | 2d | 1,110 | $484 | $537K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Other A | February 17, 2026 | February 19, 2026 | 2d | 2,584 | — | — | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell F | February 13, 2026 | February 18, 2026 | 5d | 2,283 | $488 | $1.1M | late | Form 4 ↗ | |
| VRTX | Sell S | February 11, 2026 | February 12, 2026 | 1d | 2,021 | $460 | $931K | 10b5-1 plan | Form 4 ↗ | |
| VRTX | Sell F | February 10, 2026 | February 12, 2026 | 2d | 1,127 | $468 | $528K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 19, 2026 | Form 4 | 0000875320-26-000226 | 1 | published | EDGAR ↗ |
| February 26, 2026 | Form 4 | 0000875320-26-000112 | 2 | published | EDGAR ↗ |
| February 19, 2026 | Form 4 | 0000875320-26-000088 | 4 | published | EDGAR ↗ |
| February 18, 2026 | Form 4 | 0000875320-26-000068 | 1 | published | EDGAR ↗ |
| February 12, 2026 | Form 4 | 0000875320-26-000044 | 2 | published | EDGAR ↗ |
Other insiders at VERTEX PHARMACEUTICALS INC / MA
- LEIDEN JEFFREY M Executive Chairman 31 rows
- Sachdev Amit EVP Chief Patient & Ext Af Off 21 rows
- Kewalramani Reshma CEO & President 20 rows
- Lagarde Michel Director 19 rows
- Bozic Carmen EVP and CMO 17 rows
- Tatsis Ourania EVP, Chief Reg. & Quality Off. 16 rows
- WAGNER CHARLES F JR Director 16 rows
- Biller Jonathan EVP and Chief Legal Officer 15 rows
- Ambrose Kristen SVP & Chief Accounting Officer 13 rows
- Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. 12 rows
Everyone on file, with contracts and lobbying under the company's name: VERTEX PHARMACEUTICALS INC / MA.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 10 | February 12, 2026 | May 19, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.